



Alteration of Interleukin-4, Interleukin-6 Levels, and Post-operative Pain Intensity

Beni Indra¹*^(b), Nur Indrawaty Lipoeto²^(b), Djong Hon Tjong³^(b), Sukri Rahman⁴^(b)

¹Department of Anesthesiology, Faculty of Medicine, Universitas Andalas, Padang, West Sumatera, Indonesia; ²Department of Nutrition, Faculty of Medicine, Universitas Andalas, Padang, West Sumatera, Indonesia; ³Faculty of Mathematics and Natural Science, Universitas Andalas, Padang, West Sumatera, Indonesia; ⁴Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Andalas, Padang, West Sumatera, Indonesia

Abstract

Edited by: Mirko Spiroski Citation: Indra B, Lipcet N, Tjong DH, Rahman S. Alteration of Interleukin-4, Interleukin-6 Levels, and Postoperative Pain Intensity. Open Access Maced J Med Sci. 2023 Jan 01: 11(A):1-7. https://doi.org/10.3889/oamjms.2023.10082 Keywords: Interleukin-4; Interleukin-6; Numeric rating scale; Surgical procedures; Post Operative pain intensity *Correspondence: Beni Indra, Department of Anesthesiology, Faculty of Medicine, Universitas Andalas, Padang, West Sumatera, Indonesia, E-mail: beniindra@med.unand.ac.id Received: 11-May-2022 Revised: 31-Jul-2022 Accepted: 19-Dec-2022 Copyright: © 2023 Beni Indra, Nur Indrawaty Lipoeto, Djong Hon Tjong, Sukri Rahman Funding: This research did not receive any financial support

Funding: This research did not receive any infancial support Competing Interests: The authors have declared that no competing interests exist Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (Cc BY-NC 4.0) **INTRODUCTION:** Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. Pain can be both a symptom of tissue trauma associated with surgery or disease in itself. Surgical procedures may induce different alterations of interleukin (IL)-4 and IL-6 that affect the variation of pain intensity during surgery. Therefore, appropriate pain management during a surgical procedure may reduce postoperative morbidity caused by surgical pain.

METHODS: This prospective cohort study included patients by consecutive sampling from all general anaesthetic patients in Dr. M Djamil Hospital and Andalas University Hospital, Padang, West Sumatera. We collected data from early November 2021 until the end of January 2022 and got 90 patients that suit the criteria. All patients signed informed consent to check their interleukin level and pain intensity before and after surgery. We assessedIL-4 and IL-6 using the Sandwich-ELISA technique and pain intensity using the numeric rating scale (NRS). We also measured length of surgery and its correlation to IL-4, IL-6, and NRS score. Patients were anesthetized with General Anesthesia and received the same fentanyl range of dosage (3-5) mcg/kg Ketorolac 30 mg and Tramadol 100 mg intravenous were given for postoperative analgesia.

RESULT: We found a significant correlation between Δ IL-6 with surgical procedures, Δ NRS score, and length of surgery p = 0.039, p = 0.002, and p = 0.008, respectively). Whereas Δ IL-4 shows no significant correlation to surgical procedures, Δ NRS score, and length of operation (0.868, 0.195, and 0.112, respectively). Our result also found a significant correlation between Δ NRS and surgical procedures (p = 0.013).

CONCLUSION: Surgical procedures with severe tissue trauma may trigger high secretion of Δ IL6 and stimulate high pain intensity after the surgical procedure.

Introduction

According to the International Association for the Study of Pain (2020), pain is "An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage." Pain is always a personal experience influenced by biological factors, psychological, and social in different levels [1]. Pain may last from hours to weeks and is associated with acute tissue damage or trauma, inflammation, a surgical procedure, or a straightforward disease process. Fentanyl is the potent synthetic opioid frequently used as an analgetic in intubated patients and severe cases of pain. Nevertheless, there is an individual's variability in response to fentanyl that causes the dosage from one patient and others to be different [2].

Based on immunology theory, interleukin (IL)-6 as a pro-inflammation cytokine has a rule in pain modulation. The Janus-activated kinase/signal transducer activator of transcription (JAK/STAT) is the most well-studied pathway that is activated as a

Open Access Maced J Med Sci. 2023 Jan 01; 11(A):1-7.

response to signal-transducing cytokine receptors. It can sensitize nociceptive receptors and reinforce pain stimulation [3]. Surgical procedures induce elevated IL-6 in the first 3 h and variations of surgical procedures and post-operative management may influence discrepancies in the magnitude of IL-6 elevation [4].

On the other hand, tissue trauma and destruction also release an anti-inflammation cytokine that has the opposite rule to IL-6. One of the anti-inflammation cytokine in pain modulation is IL-4 which acts as a pleiotropic regulator and neuroprotection. The beneficial effect of IL-4 is the inhibition of production and release of proinflammation cytokine, chemokine, protease, and reactive oxygen species [5]. IL-4 could induce macrophages M2 to produce endogen opioids and triggered peripheral opioid receptors to reduce pain sensation [6]. We, therefore, assessed the comparison between several surgeries on releasing IL4 and IL6 and count the numeric rating scale (NRS) to show the pain intensity experienced by the patient. Our aim in this research is to analyze the correlation between the alteration of IL-4 and IL-6 and the patient's response to pain after surgery. We also analyze between length of surgery and IL-4, IL-6, and NRS score among surgical procedures.

Patients and Methods

Patients

This prospective cohort study recruited patients by consecutive sampling method from all elective general anesthetic patients in Dr. M Djamil Hospital and Andalas University Hospital, Padang, West Sumatera, Indonesia. The patient must not routine consume opioid and don't have psychiatric, neurologic, or chronic pain issues and the range of age is between 16 and 65 years old. We collected data from all surgery that suit the criteria in early November 2021 until the end of January 2022 and got 90 patients. All patients signed informed consent to have their interleukin plasma level and the NRS score checked before and after surgery. Patients received the same fentanyl range of dosage (3–5 mcg/kg) when induction state and Ketorolac 30 mg and Tramadol 100 mg intravenous for postoperative analgesia.

Data and sample collecting procedures

The patient's history was collected through Medical records and direct dialogue with patients. We assessed pain intensity using the NRS score before the surgical procedure and excluded if the NRS score was >3. We collected 2 mL of blood just after induction of the anesthetic procedure and at the end of the surgery. Post-surgical NRS score assessed after patients wake in Post-Anesthesia Care Unit (PACU).

Measurement of cytokine level

Blood in EDTA tubes was centrifuged at 4000 rpm for 10 min. After the centrifugation, plasma was kept at -80°C before measurement. The isolation of IL-4 and IL-6 was done in Andalas University Biomedic Laboratory and measure using the Sandwich-ELISA technique. Optical density (OD) was measured by spectrophotometric in 450 nm \pm 2 nm wavelength. Human IL-4 and IL-6 can be counted by comparing OD samples with a standard curve

Statistics

We used SPSS Statistics 26 application to analyze all of the data. Wilcoxon test was performed to compare the levels of IL-4 and IL-6 before and after surgery. The correlation between interleukin with NRS score on each surgery was measured by Spearman's correlation analysis. The differences in variables between surgery groups were examined by Kruskal–Wallis test. Values of p < 0.05 were considered significant. Correlation between length of surgery and IL-4, IL-6, and NRS score measured using Pearson test. Several confounding variables were controlled by Spearman and Mann–Whitney analyses such as age and gender, respectively.

Ethical consideration

This research involves humans as research subjects. The ethical implications of this research follow the provisions of the Declaration of Helsinki and have passed the ethical test from the ethics committee of the Faculty of Medicine, Universitas Andalas Padang with number 574/ UN.16.2/KEP-FK/2021. All medical matters relating to this research are confidential. Research subjects have the right to refuse to participate in the study if they do not agree.

Results

Out of 90 patients, 58 of them are females (64.4%) and 32 are males (35.6%) with ages ranging from 16 to 65 years old (mean 43.79 \pm 14.8 years). Hypertension is the most frequent comorbidities of the subject (11.1%). The majority of patients' American Society of Anesthesiologists (ASA) score is 2. Laparoscopy and laparotomy are the most frequent surgery in this study (28.6% and 26.7%) (Table 1).

The highest Δ IL-4 level is on the removal tumor surgery followed by laparoscopy (0.6 and 0.4, respectively) (Figure 1). Meanwhile, Δ IL-6 was found highest in laparotomy and Open Reduction Internal Fixation operations (ORIF) as shown in Figure 2 (381.6 and 176.8, respectively). The alteration of NRS scores was found high in laparotomy followed by stabilization and decompression surgery (2.4 and 2.2, respectively) (Figure 3). Tympanomastoidectomy has the longest operation time (4.5 h) (Figure 4) and got the highest dosage of fentanyl (300 mg) (Figure 5).



Figure 1: The average IL-4 value before and after surgery

Table 1: Demographic data

N = 90 Gender (female-male) 32–58 Age (years), median (IQR) 42.79 (16–65) ASA 1 1 1 (1.1) 2 81 (90) 3 8 (8.9) Surgical procedures 26 (28.6%) Laparoscopic cholexystectomy 15 (16.7) Laparoscopic oblexitor 2 (2.2) Laparoscopic low anterior resection 2 (2.2) Laparoscopic repair hernia 4 (4.4) Laparoscopic low anterior resection 2 (2.6,7%) Laparotomy 24 (26.7%) Exploratory laparotomy 11 (1.1) Splenectomy repair fistula 1 (1.1) Splenectomy repair fistula 3 (3.3) ORIF mandible 3 (3.3) ORIF davicle 3 (3.3) ORIF favicle 3 (3.3) Turnor excision 5 (5.6) Herniman	Characteristic	All patients
Gender (female-male) 32–58 Age (years), median (IQR) 42.79 (15–65) ASA 1 1 (1.1) 2 81 (90) 3 8 (8.9) Surgical procedures 26 (28.6%) Laparoscopic cholecystectomy 15 (16.7) Laparoscopic cadhesiolysis 3 (3.3) Laparoscopic cadhesiolysis 3 (3.3) Laparoscopic repair hernia 4 (4.4) Laparoscopic repair hernia 4 (4.4) Laparotomy (22.2) 22.2) Exploratory laparotomy 17 (18.9) Laparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Splenctomy 1 (1.1) ORIF mandible 3 (3.3) ORIF familibration (ORIF) 11 (12.1%) ORIF familibration 1 (1.1) ORIF mandible 2 (2.2) ORIF familibration 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hernimandibulectomy 1 (1.1) Total thyroidectomy 1 (1.1)		N = 90
Age (vears), median (IQR) 42.79 (16–65) ASA 1 1 1 (1.1) 2 81 (90) 3 8 (8.9) Surgical procedures 26 (28.6%) Laparoscopic cholecystectomy 15 (16.7) Laparoscopic condexition 1 (1.1) Laparoscopic condexition 2 (2.2) Laparoscopic low anterior resection 2 (2.2) Laparoscopic hemicolectomy 1 (1.1) Laparoscopic hemicolectomy 1 (1.1) Laparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Spienectomy 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF mandible 3 (3.3) ORIF radial 1 (1.1) ORIF radial 1 (1.1) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Turmer excision 5 (5.6) Hemimandibulectomy 1 (1.1) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Turmer excision 5 (5.6) Hemimandibulectomy 2 (2.2)	Gender (female-male)	32–58
ASA 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Age (years), median (IQR)	42.79 (16-65)
1 1 (1 1) 2 81 (90) 3 8 (8.9) Surgical procedures 6 (8.9) Laparoscopic cholecystectomy 15 (16.7) Laparoscopic adhesiolysis 3 (3.3) Laparoscopic chow anterior resection 2 (2.2) Laparoscopic chomicolectomy 1 (1.1) Laparoscopic hemicolectomy 1 (1.1) Departomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Splenectomy 1 (1.1) ORIF cavicle 3 (3.3) ORIF mandible 3 (3.3) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) ORIF fadial 1 (1.1) ORIF dial 1 (1.1) ORIF dial 1 (1.1) Tumor excision 5 (5.6) </td <td>ASA</td> <td></td>	ASA	
2 81 (90) 3 8 (8.9) Surgical procedures Laparoscopy Laparoscopic cholecystectomy 15 (16.7) Laparoscopic exploration 1 (1.1) Laparoscopic repair hernia 2 (2.2) Laparoscopic repair hernia 4 (4.4) Laparoscopic hemicolectomy 1 (1.1) Laparoscopic repair hernia 4 (4.4) Laparotomy aparotomy 17 (18.9) Laparotomy repair fistula 1 (1.1) Splenctomy repair fistula 3 (3.3) ORIF mandible 3 (3.3) ORIF nandible 3 (3.3) ORIF fandible 3 (3.3) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) ORIF maxillofacial 1 (1.1) ORIF maxillofacial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (2.2) Tumor excision 5 (5.6) Hermimandibulectomy 1 (1.1) Orbif eatical mastectomy 2 (2.2) Wide excision 6 (6.7) Tonsillectom	1	1 (1.1)
3 8 (8.9) Surgical procedures Laparoscopy 26 (28.6%) Laparoscopic cholecystectomy 15 (16.7) Laparoscopic adhesiolysis 3 (3.3) Laparoscopic owanterior resection 2 (2.2) Laparoscopic pain hernia 4 (4.4) Laparoscopic hericolectomy 1 (1.1) Laparoscopic pain hernia 4 (4.4) Laparoscopic hericolectomy 1 (1.1) Laparoscopic hericolectomy 1 (1.1) Laparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Spienectomy 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF mandible 3 (3.3) ORIF radial 1 (1.1) ORIF radial 1 (1.1) ORIF radial 1 (1.1) Removal tumor 22 (2.2) Midified radical mastectomy 4 (4.4) Modified radical mastectomy 2 (2.2) Midified radical mastectomy 2 (2.2) Midified radical mastectomy 2 (2.2) Midified radical mastectomy 2 (2.2) <	2	81 (90)
Surgical procedures26 (28.6%)Laparoscopy15 (16.7)Laparoscopic cholecystectomy15 (16.7)Laparoscopic adhesiolysis3 (3.3)Laparoscopic adhesiolysis3 (3.3)Laparoscopic low anterior resection2 (2.2)Laparoscopic hemicolectomy1 (1.1)Laparotomy24 (26.7%)Exploratory laparotomy17 (18.9)Laparotomy debulking5 (5.6)Relaparotomy repair fistula1 (1.1)Splenectomy reduction internal fixation (ORIF)11 (12.1%)ORIF mandible3 (3.3)ORIF clavicle3 (3.3)ORIF fadial1 (1.1)ORIF fadial1 (1.1)ORIF fadial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor22 (2.2)ORIF fadial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor22 (24.2%)Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy2 (2.2)Maxillectomy1 (1.1)Timpanomastoidectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)L-4 before surgery (pg/mL), median (IQR)3.61 (2.5-37.9)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5-37.9)L-4 after surgery (pg/mL), median (IQ	3	8 (8.9)
Laparoscopy 26 (28.6%) Laparoscopic cholecystectomy 15 (16.7) Laparoscopic adhesiolysis 3 (3.3) Laparoscopic adhesiolysis 3 (3.3) Laparoscopic repair hemia 4 (4.4) Laparotomy 1 (1.1) Laparotomy debulking 5 (5.6) Relaparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF clavicle 3 (3.3) ORIF fadial 1 (1.1) ORIF radial 1 (1.1) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) Modified radical mastectomy 2 (2.2) Wide excision 6 (6.7) Tonsillectomy 2 (2.2) Maxillectomy 1 (1.1)	Surgical procedures	
Laparoscopic cholecystectomy 15 (16.7) Laparoscopic adhesiolysis 3 (3.3) Laparoscopic adhesiolysis 3 (3.3) Laparoscopic low anterior resection 2 (2.2) Laparoscopic nepair hernia 4 (4.4) Laparoscopic hemicolectomy 1 (1.1) Laparotomy 24 (26.7%) Exploratory laparotomy 17 (18.9) Laparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF mandible 3 (3.3) ORIF radial 1 (1.1) ORIF mandiblectomy 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hernimandibulectomy 1 (1.1) Modified radical mastectomy 2 (2.2) Wide excision 6 (6.7) Tonsillectomy 2 (2.2)	Laparoscopy	26 (28.6%)
Laparoscopic exploration1 (1, 1)Laparoscopic dwanterior resection2 (2, 2)Laparoscopic repair hernia4 (4.4)Laparoscopic hermicolectomy1 (1, 1)Laparoscopic hermicolectomy24 (26.7%)Exploratory laparotomy24 (26.7%)Laparotomy1 (1, 1)Splenectomy1 (1, 1)Splenectomy1 (1, 1)ORIF clavicle3 (3, 3)ORIF nandible3 (3, 3)ORIF radial1 (1, 1)ORIF maxillofacial1 (1, 1)Removal tumor22 (24.2%)Tumor excision5 (5, 6)Hernimandibulectomy4 (4, 4)Modified radical mastectomy2 (2, 2)Wide excision6 (6, 7)Tonsillectomy1 (1, 1)Orchidectomy1 (1, 1)Maxillectomy2 (2, 2)Wide excision5 (5, 6%)Laminectomy3 (3, 3)Spinal fusion2 (2, 2)Comorbid1Hypertension10 (11, 1)Type 2 diabetes4 (4, 4)Asthma1 (1, 1)L-4 after surgery (pg/mL), median (IQR)3 (6, 7, -125, 4)L-6 defore surgery (pg/mL), median (IQR)20, 7, 34 (66, 1-226, 4)L-6 defore surgery (pg/mL), median (IQR)44, 2 ((-4	Laparoscopic cholecystectomy	15 (16.7)
Laparoscopic adhesiolysis3 (3.3)Laparoscopic low anterior resection2 (2.2)Laparoscopic repair hernia4 (4.4)Laparoscopic hemicolectomy1 (1.1)Laparotomy24 (26.7%)Exploratory laparotomy17 (18.9)Laparotomy debulking5 (5.6)Relaparotomy repair fistula1 (1.1)Splenectomy1 (1.1)Open reduction internal fixation (ORIF)11 (12.1%)ORIF mandible3 (3.3)ORIF clavicle3 (3.3)ORIF fumeral2 (2.2)ORIF radial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor22 (24.2%)Tumor exclsion5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy1 (1.1)Total thyroidectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy2 (2.2)Maxillectomy2 (2.2)Maxillectomy2 (2.2)Maxillectomy2 (2.2)Maxillectomy2 (2.2)Maxillectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)L-4 before surgery (pg/mL), median (IQR)3.61 (2.5–37.9)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)L-4 after surgery (pg/mL), median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)44.2 ((-	Laparoscopic exploration	1 (1.1)
Laparoscopic low anterior resection2 (2.2)Laparoscopic hemicolectomy1 (1.1)Laparoscopic hemicolectomy14 (1.1)Laparotomy24 (26.7%)Exploratory laparotomy17 (18.9)Laparotomy debulking5 (5.6)Relaparotomy repair fistula1 (1.1)Splenectomy1 (1.1)ORIF mandible3 (3.3)ORIF numeral2 (2.2)ORIF radial1 (1.1)ORIF maxillofacial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor22 (24.2%)Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy2 (2.2)Maxillectomy1 (1.1)Timpanomastoidectomy2 (2.2)Maxillectomy1 (1.1)Timpanomastoidectomy2 (2.2)Comorbid1 (1.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5-37.9)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5-37.9)L-4 after surgery (pg/mL), median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)1.10-3NRS score after surgery, median (IQR)3 (1-7)<	Laparoscopic adhesiolysis	3 (3.3)
Laparoscopic repair hernia 4 (4.4) Laparoscopic hemicolectomy 1 (1.1) Laparotomy 24 (26.7%) Exploratory laparotomy 17 (18.9) Laparotomy repair fistula 1 (1.1) Spienectomy 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF clavicle 3 (3.3) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hernimandibulectomy 1 (1.1) Total thyroidectomy 4 (4.4) Modified radical mastectomy 2 (2.2) Maxillectomy 1 (1.1) Orchidectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) Maxillectomy 2 (2.2) Maxillectomy 1 (1.1) Timpanomastoidectomy 3 (3.3)<	Laparoscopic low anterior resection	2 (2.2)
Laparoscopic hemicolectomy 1 (1.1) Laparotomy 24 (26.7%) Exploratory laparotomy 17 (18.9) Laparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Splenectomy 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF mandible 3 (3.3) ORIF clavicle 3 (3.3) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) Total thyroidectomy 4 (4.4) Modified radical mastectomy 2 (2.2) Wide excision 6 (6.7) Tonsillectomy 1 (1.1) Orchidectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) Maxillectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) </td <td>Laparoscopic repair hernia</td> <td>4 (4.4)</td>	Laparoscopic repair hernia	4 (4.4)
Laparotomy 24 (26.7%) Exploratory laparotomy 17 (18.9) Laparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Splenectomy 11 (12.1%) ORIF mandible 3 (3.3) ORIF radial 1 (1.1) ORIF mandible 3 (3.3) ORIF favicle 3 (3.3) ORIF favicle 3 (3.3) ORIF mandible 2 (2.2) ORIF maxillofacial 1 (1.1) ORIF maxillofacial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) Total thyroidectomy 4 (4.4) Modified radical mastectomy 2 (2.2) Wide excision 6 (6.7) Tonsillectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) Maxilication and decompression 5 (5.6%) Laminectomy 3 (3.3) Spinal fusion 2 (2.2) Comorbid 1 (1.1)	Laparoscopic hemicolectomy	1 (1.1)
Exploratory laparotomy 17 (18.9) Laparotomy debulking 5 (5.6) Relaparotomy repair fistula 1 (1.1) Spienectomy 1 (1.1) ORIF clavicle 3 (3.3) ORIF function 1 (1.1) ORIF clavicle 3 (3.3) ORIF function 1 (1.1) ORIF clavicle 3 (3.3) ORIF function 1 (1.1) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) Total thyroidectomy 4 (4.4) Modified radical mastectomy 2 (2.2) Maxillectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) Comorb	Laparotomy	24 (26.7%)
Laparotomy debulking 5 (5.6)Relaparotomy repair fistula1 (1.1)Splenectomy1 (1.1)ORIF clavicle3 (3.3)ORIF clavicle3 (3.3)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF tibial1 (1.1)ORIF tibial1 (1.1)ORIF tibial1 (1.1)ORIF tibial1 (1.1)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF radial1 (1.1)Removal tumor 22 (24.2%) Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Impanmastoidectomy2 (2.2)Maxillectomy1 (1.1)Orchidectomy1 (1.1)Impanmastoidectomy2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 before surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)44.2 ((-417)-2010.4)NRS score after surgery (pg/mL), median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1-7)ANRS, median (IQR)3 (1-7)ANRS, median (IQR)3 (1-7)	Exploratory laparotomy	17 (18.9)
Relaparotomy repair fistula 1 (1.1) Splenectomy 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF mandible 3 (3.3) ORIF randible 3 (3.3) ORIF radial 1 (1.1) ORIF radial 1 (1.1) ORIF radial 1 (1.1) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) Total thyroidectomy 4 (4.4) Modified radical mastectomy 2 (2.2) Wide excision 6 (6.7) Tonsillectomy 2 (2.2) Maxillectomy 1 (1.1) Orchidectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) Maxillectomy 3 (3.3) Spinal fusion 2 (2.2) Comorbid 10 (11.1) Hypertension 10 (11.1) Type 2 diabetes 4 (4.4) Asthma 1 (1.1) L-4 after	Laparotomy debulking	5 (5.6)
Splenectomy 1 (1.1) Open reduction internal fixation (ORIF) 11 (12.1%) ORIF mandible 3 (3.3) ORIF clavicle 3 (3.3) ORIF radial 2 (2.2) ORIF radial 1 (1.1) ORIF maxillofacial 1 (1.1) ORIF maxillofacial 1 (1.1) ORIF maxillofacial 1 (1.1) Removal tumor 22 (24.2%) Tumor excision 5 (5.6) Hemimandibulectomy 1 (1.1) Total thyroidectomy 4 (4.4) Modified radical mastectomy 2 (2.2) Wide excision 6 (6.7) Tonsillectomy 1 (1.1) Orchidectomy 1 (1.1) Orchidectomy 2 (2.2) Maxillectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) Maxillectomy 1 (1.1) Timpanomastoidectomy 2 (2.2) Comorbid 1 (1.1) Hypertension 10 (11.1) Type 2 diabetes 4 (4.4) Asthma 1 (1.1) L-4 b	Relaparotomy repair fistula	1 (1.1)
Open reduction internal fixation (ORIF)11 (12.1%)ORIF mandible3 (3.3)ORIF clavicle3 (3.3)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor22 (24.2%)Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2)Maxillectomy1 (1.1)Timpanomastoidectomy2 (2.2)Stabilization and decompression5 (5.6%)Larminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 before surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)3 (1-7)ANRS, median Scoley (f Amethesiologists.	Splenectomy	1 (1.1)
ORIF mandible3 (3.3)ORIF clavicle3 (3.3)ORIF clavicle3 (3.3)ORIF humeral2 (2.2)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor22 (24.2%)Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2)Maxilleatomy1 (1.1)Timpanomastoidectomy2 (2.2)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)0.08 ([-3.2]–8.4)IL-6 before surgery (pg/mL), median (IQR)207.34 (65.1–2246.4)AlL 6 (pg/mL), median (IQR)44.2 ((-417)–2010.4)NRS score after surgery, median (IQR)3 (1-7)ANRS, median (IQR)3 (1-7)ANRS, median GIQR3 (1-7)	Open reduction internal fixation (ORIF)	11 (12.1%)
ORIF clavicle 3 (3.3)ORIF humeral 2 (2.2)ORIF radial1 (1.1)ORIF radial1 (1.1)ORIF maxillofacial1 (1.1)ORIF maxillofacial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor 22 (24.2%) Tumor excision5 (5 6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy2 (2.2)Maxillectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression 5 (5.6%) Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid1 (1.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)L-4 after surgery (pg/mL), median (IQR)44.20 (-417)-2010.4)NRS score after surgery (pg/mL), median (IQR)44.20 (-417)-2010.4)NRS score after surgery, median (IQR)3 (1-7)A NRS, median (IQR)	ORIF mandible	3 (3.3)
ORIF humeral2 (2.2)ORIF radial1 (1.1)ORIF tibial1 (1.1)ORIF tibial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor 22 (24.2%) Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2)Maxillectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression 5 (5.6%) Larninectomy3 (3.3)Spinal fusion2 (2.2)Comorbid1Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 before sugery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)148.05 (66.7–1255.4)IL-6 before surgery (pg/mL), median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)3 (1-7)ANRS, median (IQR)3 (1-7)<	ORIF clavicle	3 (3.3)
ORIF radial1 (1.1)ORIF tibial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor22 (24.2%)Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Dranoastoidectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)L-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)L-4 after surgery (pg/mL), median (IQR)207.34 (65.1–2246.4)AlL-6 (pg/mL), median (IQR)44.2 ((-417)–2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1–7)A NRS, median (IQR)3 (1–7)A NRS, median (IQR)2 (0–5)*Ash-4 merican Society of Amethesiologists.50	ORIF humeral	2 (2.2)
ORIF tibial1 (1.1)ORIF maxillofacial1 (1.1)Removal tumor 22 (24.2%) Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2)Maxillectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)0.08 (1-3.2)–8.4)IL-6 before surgery (pg/mL), median (IQR)207.34 (65.1–2246.4)AlL 6 (pg/mL), median (IQR)44.2 ((-417)–2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1-7)A NRS, median scolety of Anesthesiologists.	ORIF radial	1 (1.1)
ORIF maxillofacial1 (1.1)Removal tumor 22 (24.2%) Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy2 (2.2)Maxillectomy1 (1.1)Orchidectomy2 (2.2%)Stabilization and decompression 5 (5.6%) Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 before sugery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 before surgery (pg/mL), median (IQR)0.08 (1-3.2)= 8.4)IL-6 before surgery (pg/mL), median (IQR)148.05 (66.7–1255.4)IL-6 before surgery (pg/mL), median (IQR)44.2 ((-417)-2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1-7)A NRS, median (IQR) <td>ORIF tibial</td> <td>1 (1.1)</td>	ORIF tibial	1 (1.1)
Removal tumor22 (24.2%)Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2)Maxillectomy1 (1.1)Spinal fusion2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 before sugery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)0.08 (1-3.2)–8.4)IL-6 before surgery (pg/mL), median (IQR)148.05 (66.7–1255.4)IL-6 before surgery (pg/mL), median (IQR)44.2 ((-417)–2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1-7)A NRS, median (IQR)3 (1-7)A NRS, median (IQR)2 (0-5)	ORIF maxillofacial	1 (1.1)
Tumor excision5 (5.6)Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy2 (2.2)Maxillectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2)Maxillectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)0.08 ([-3.2]–8.4)IL-6 before surgery (pg/mL), median (IQR)207.34 (65.1–2246.4)A IL 6 (pg/mL), median (IQR)44.2 ((-417)–2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1–7)A NRS, median (IQR)3 (1–7)A NRS, median (IQR)2 (0–5)	Removal tumor	22 (24.2%)
Hemimandibulectomy1 (1.1)Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy2 (2.2)Maxillectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-6 before surgery (pg/mL), median (IQR)0.08 (1-3.2)–8.4)IL-6 before surgery (pg/mL), median (IQR)148.05 (66.7–1255.4)IL-6 before surgery (pg/mL), median (IQR)44.2 ((-417)–2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1-7)A NRS, median (IQR)3 (1-7)ANRS, median (IQR)3 (1-7)ANRS, median (IQR)3 (1-7)A NRS, median (IQR)3 (1-7)A NRS, median (IQR)3 (1-7)A NRS, median (IQR)3 (1-7)A NRS score after surgery, median (IQR)3 (1-7)A NRSSociety of Anesthesiologists	Tumor excision	5 (5.6)
Total thyroidectomy4 (4.4)Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy2 (2.2)Maxillectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 before sugery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)0.08 (1-3.2)–8.4)IL-6 before surgery (pg/mL), median (IQR)148.05 (66.7–1255.4)IL-6 before surgery (pg/mL), median (IQR)44.2 ((-417)–2010.4)AlL 6 (pg/mL), median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1-7)ANRS, median (IQR)3 (1-7)ANRS, median (IQR)2 (0-5)*58A: American Society of Ameritaesiologists.	Hemimandibulectomy	1 (1.1)
Modified radical mastectomy2 (2.2)Wide excision6 (6.7)Tonsillectomy2 (2.2)Maxillectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)0.08 ([-3.2]– 8.4)IL-6 before surgery (pg/mL), median (IQR)207.34 (65.1–2246.4)A IL 6 (pg/mL), median (IQR)44.2 ((-417)– 2010.4)NRS score after surgery, median (IQR)1 (0-3)NRS score after surgery, median (IQR)3 (1–7)A NRS, median (IQR)2 (0–5)*SAX-American Society of Anesthesiologists.5	Total thyroidectomy	4 (4,4)
Wide excision6 (6.7)Tonsillectomy2 (2.2)Maxillectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid10 (11.1)Hypertension10 (11.1)Type 2 diabetes4 (4.4)Asthma1 (1.1)IL-4 after surgery (pg/mL), median (IQR)3.61 (2.5–37.9)IL-4 after surgery (pg/mL), median (IQR)0.08 ([-3.2]–8.4)IL-6 before surgery (pg/mL), median (IQR)148.05 (66.7–1255.4)IL-6 before surgery (pg/mL), median (IQR)207.34 (65.1–2246.4)A IL 6 (pg/mL), median (IQR)44.2 ((-417)–2010.4)NRS score after surgery, median (IQR)3 (1-7)A NRS, median (IQR)3 (1-7)A NRS, median (IQR)2 (0-5)	Modified radical mastectomy	2 (2.2)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Wide excision	6 (6.7)
Maxillectomy1 (1.1)Orchidectomy1 (1.1)Timpanomastoidectomy2 (2.2%)Stabilization and decompression5 (5.6%)Laminectomy3 (3.3)Spinal fusion2 (2.2)Comorbid	Tonsillectomy	2 (2.2)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Maxillectomy	1 (1.1)
Timpanomastoidectomy 2 (2.2%) Stabilization and decompression 5 (5.6%) Laminectomy 3 (3.3) Spinal fusion 2 (2.2) Comorbid 10 (11.1) Hypertension 10 (11.1) Type 2 diabetes 4 (4.4) Asthma 1 (1.1) IL-4 before sugery (pg/mL), median (IQR) 3.61 (2.5–37.9) IL-4 after surgery (pg/mL), median (IQR) 0.08 (1-3.2)= 8.4) IL-6 before surgery (pg/mL), median (IQR) 0.08 (1-3.2)= 8.4) IL-6 before surgery (pg/mL), median (IQR) 148.05 (66.7–1255.4) IL-6 before surgery (pg/mL), median (IQR) 207.34 (65.1–2246.4) A IL 6 (pg/mL), median (IQR) 44.2 ((-417)–2010.4) NRS score before surgery, median (IQR) 1 (0-3) NRS score after surgery, median (IQR) 3 (1-7) A NRS, median (IQR) 3 (1-7) A NRS, median (IQR) 2 (0-5) * SA*A merican Society of Anesthesiologists. 5454.	Orchidectomy	1 (1.1)
Stabilization and decompression 5 (5.6%) Laminectomy 3 (3.3) Spinal fusion 2 (2.2) Comorbid 10 (11.1) Hypertension 10 (11.1) Type 2 diabetes 4 (4.4) Asthma 1 (1.1) IL-4 before sugery (pg/mL), median (IQR) 3.61 (2.5–37.9) IL-4 after surgery (pg/mL), median (IQR) 0.08 (1-3.2]– 8.4) IL-6 before surgery (pg/mL), median (IQR) 148.05 (66.7–1255.4) IL-6 after surgery (pg/mL), median (IQR) 44.2 ((4.17)– 2010.4) NRS score before surgery, median (IQR) 10–3) NRS score after surgery, median (IQR) 1 (0–3) NRS, median (IQR) 3 (1–7) A NRS, median (IQR) 2 (0–5)	Timpanomastoidectomy	2 (2.2%)
Laminectomy 3 (3.3) Spinal fusion 2 (2.2) Comorbid	Stabilization and decompression	5 (5.6%)
Spinal fusion 2 (2.2) Comorbid 10 (11.1) Hypertension 10 (11.1) Type 2 diabetes 4 (4.4) Asthma 1 (1.1) IL-4 before sugery (pg/mL), median (IQR) 3.61 (2.5–37.9) IL-4 after surgery (pg/mL), median (IQR) 0.08 ([-3.2]– 8.4) IL-6 before surgery (pg/mL), median (IQR) 207.34 (65.1–2246.4) A IL 6 (pg/mL), median (IQR) 207.34 (65.1–2246.4) A IL 6 (pg/mL), median (IQR) 44.2 (-417)– 2010.4) NRS score after surgery, median (IQR) 1 (0-3) NRS, median (IQR) 3 (1–7) A NRS, median (IQR) 2 (0–5) * X8A: American Society of Anesthesiologists. 5454.	Laminectomy	3 (3.3)
	Spinal fusion	2 (2.2)
Hypertension 10 (11.1) Type 2 diabetes 4 (4.4) Ashma 1 (1.1) IL-4 before sugery (pg/mL), median (IQR) 3.61 (2.5–37.9) IL-4 after surgery (pg/mL), median (IQR) 3.7 (3–34.7) AlL-4 (pg/mL), median (IQR) 0.08 ([-3.2]– 8.4) IL-6 before surgery (pg/mL), median (IQR) 148.05 (66.7–1255.4) IL-6 after surgery (pg/mL), median (IQR) 207.34 (65.1–2246.4) A IL 6 (pg/mL), median (IQR) 44.2 ((-417)– 2010.4) NRS score before surgery, median (IQR) 1 (0–3) NRS score after surgery, median (IQR) 3 (1–7) Δ NRS, median (IQR) 2 (0–5) *58:A- merican Society of Anesthesiologists. 5	Comorbid	
Type 2 diabetes 4 (4.4) Asthma 1 (1.1) L4 before sugery (pg/mL), median (IQR) 3.61 (2.5–37.9) LL-4 after surgery (pg/mL), median (IQR) 3.7 (3–34.7) ΔLL-4 (pg/mL), median (IQR) 0.08 ([-3.2]– 8.4) LL-6 before surgery (pg/mL), median (IQR) 148.05 (66.7–1255.4) LL-6 after surgery (pg/mL), median (IQR) 207.34 (65.1–2246.4) Δ LE 6 (pg/mL), median (IQR) 44.2 ((-417)– 2010.4) NRS score after surgery, median (IQR) 1 (0–3) NRS, median (IQR) 2 (0–5) ×58:A-merican Society of Anesthesiologists. 5.3	Hypertension	10 (11.1)
Asthma 1 (1.1) IL-4 before sugery (pg/mL), median (IQR) 3.61 (2.5–37.9) IL-4 after surgery (pg/mL), median (IQR) 3.7 (3–34.7) AlL-4 (pg/mL), median (IQR) 0.08 ([-3.2]– 8.4) IL-6 before surgery (pg/mL), median (IQR) 148.05 (66.7–1255.4) IL-6 defore surgery (pg/mL), median (IQR) 207.34 (65.1–2246.4) Δ IL 6 (pg/mL), median (IQR) 44.2 ((-417)– 2010.4) NRS score before surgery, median (IQR) 1 (0–3) NRS, median (IQR) 3 (1–7) Δ NRS, median (IQR) 2 (0–5) * S&A: American Society of Anesthesiologists. 5	Type 2 diabetes	4 (4.4)
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Asthma	1 (1.1)
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	IL-4 before sugery (pg/mL), median (IQR)	3.61 (2.5-37.9)
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	IL-4 after surgery (pg/mL), median (IQR)	3.7 (3–34.7)
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	AlL-4 (pg/mL), median (IQR)	0.08([-3.2]-8.4)
IL-6 after surgery (pg/mL), median (IQR) 207.34 (65.1–2246.4) Δ IL 6 (pg/mL), median (IQR) 44.2 ((-417)– 2010.4) NRS score before surgery, median (IQR) 1 (0–3) NRS score after surgery, median (IQR) 3 (1–7) Δ NRS, median (IQR) 2 (0–5) *SA: American Society of Anesthesiologists. 3	IL-6 before surgery (pg/mL), median (IQR)	148.05 (66.7–1255.4)
ALL 6 (og/mL), median (IQR) 44.2 ((-417) – 2010.4) NRS score before surgery, median (IQR) 1 (0–3) NRS score after surgery, median (IQR) 3 (1–7) Δ NRS, median (IQR) 2 (0–5) *S&: American Society of Anesthesiologists 5	II -6 after surgery (pg/mL), median (IQR)	207 34 (65 1–2246 4)
NRS score after surgery, median (IQR) 1 (0–3) NRS score after surgery, median (IQR) 3 (1–7) Δ NRS, median (IQR) 2 (0–5) *SA: American Society of Anesthesiologists 5	$\Lambda \parallel 6 (pq/ml) median (IQR)$	44.2((-417) - 20104)
NRS score after surgery, median (IQR) 3 (1–7) A NRS, median (IQR) 2 (0–5) *ASA: American Society of Anesthesiologists. 3	NRS score before surgery median (IQR)	1 (0-3)
A NRS, median (IQR) 2 (0–5) *ASA: American Society of Anesthesiologists.	NRS score after surgery, median (IQR)	3 (1-7)
*ASA: American Society of Anesthesiologists.	A NRS median (IQR)	2 (0-5)
	*ASA: American Society of Anesthesiologists	= (0 0)

After analyzed correlation between confounding variables, like: Age and gender with IL-4, IL-6, and NRS score before and after surgery. We used spearman test for analyzed correlation between age with IL-4, IL-6 and NRS score (p > 0.05, among each variables). Mann–Whitney test we used to analyzed between



Figure 2: The average IL-6 value before and after surgery



Figure 3: The average NRS value before and after surgery

gender with IL-4, IL-6, and NRS score (p > 0.05, among each variables).



Figure 4: The average length of surgery for each surgical procedure

We analyzed the comparison between IL-4, IL-6, and NRS before and after surgery. The results showed that there was no significant difference between IL-4 before and after surgery in each surgical procedure (Table 2). But on the contrary, there were significant difference between IL-6 and NRS score before and after surgery in each surgical procedure except IL-6 for stabilization and decompression. Tympanomastoidectomy was not



Figure 5: The average fentanyl used in each surgical procedures

Table 2: The comparison of IL-4 before and after surgery in each surgical procedures

IL-4 Before and After Surgery	Laparoscopy	Laparotomy	ORIF	Removal tumor	Stabilization and decompression
IL-4 before surgery, median (IQR)	3.68 (2.8-7.3)	3.56 (3.1–37.9)	3.44 (3-6.1)	3.71 (2.5–15.7)	3.61 (3.1–4.1)
IL-4 after surgery, median (IQR)	3.74 (3-7.5)	3.59 (3-34.7)	3.87 (3.2-5.3)	3.72 (3.1–24.1)	3.53 (3.1-4.5)
р	0.258	0.83	0.24	0.313	0.465

- Tolfferences between before and after surgery groups in each surgical procedure were analyzed with Wilcoxon test. ORIF: Open reduction internal fixation, IL: Interleukin, IQR: Interquartile Range.

included because there were only two samples in the study (Tables 3 and 4).



Figure 6: Linear correlation between IL-6 after surgery and NRS after surgery in all patients.

Based on Tables 3 and 4, it showed that mostly IL-6 concentration and NRS score always tend to increase significantly in each surgical procedure (p < 0.04).

We found significant difference of IL-6 after surgery, Δ IL-6 and Δ NRS score among each surgical procedures (p = 0.003 in three comparison test) (Table 5).



Figure 7: Linear correlation between IL-6 after surgery and NRS after surgery in laparotomy procedure

The correlation between IL-6 after surgery and NRS after surgery in all patients showed significant association (r = +0.25, p = 0.01), Δ IL-6 and Δ NRS also found significant (r = +0.32, p = 0.002). We also examined the correlation of Interleukins after surgery and NRS score in each surgical procedures. There were significant correlation between IL-6 after surgery and NRS after surgery in laparotomy procedure (r = +0.47, p = 0.01) (Table 5). Significant correlation

also found between Δ IL-6 and Δ NRS in stabilization and decompression procedure (r = +0.97, p = 0.01) (Table 6).

We found positive linear correlation between IL-6 after surgery and NRS after surgery in all patients. (r = +0.25, p = 0.01) (Figure 6).

We found positive linear correlation between IL-6 after surgery and NRS after surgery in laparotomy procedure. (r = +0.47, p = 0.01) (Figure 7).

We found positive linear correlation between Δ IL-6 and Δ NRS in all patients. (r = +0.32, p = 0.002) (Figure 8).

We found positive linear correlation between Δ IL-6 and Δ NRS in stabilization and decompression (r = +0.97, p = 0.01) (Figure 9 and Table 7). The correlation between total fentanyl used and length of operation with Δ IL-4 and Δ IL-6.

We found positive linear correlation between Length of Operation and Δ IL-6. (r = +0.27, p = 0.008) (Figure 9).



Figure 8: Linear Correlation Between ΔIL-6 and ΔNRS in all patients

Discussion

Our data showed a statistically significant difference of IL-6 after surgery, Δ IL-6 and Δ NRS among each surgical procedure. We noticed that the difference in surgical procedures could influence the degree of the inflammatory response, which in turn causes variations of cytokine secretion. To minimize the heterogeneity, we divided the surgical procedure into given groups (Laparotomy, Laparoscopy, Open Reduction Internal Fixation, Tympanomastoidectomy, and Removal Tumor) [Figure 10]. To minimize the heterogeneity of opioid usage, patients received the same fentanyl range of dosage

 Table 3: The comparison of IL-6 before and after surgery in each surgical procedure

IL-6 Before and After Surgery	Laparoscopy	Laparotomy	ORIF	Removal Tumor	Stabilization and Decompression
IL-6 before surgery, median (IQR)	112 (66.7-522.5)	167.7 (81.1-1103.5)	155.1 (89-1255)	149.5 (86-829)	156.5 (102-572)
IL-6 after surgery, median (IQR)	160 (65.1-515.2)	397.8 (90.4-2246.4)	197.8 (102-1862)	254.9 (82.8-1051)	163.7 (90-546)
р	0.007	0.001	0.006	0.006	0.893

*Differences between before and after surgery groups in each surgical procedure were analyzed with Wilcoxon test. Bold figures indicate statistical significance. ORIF: Open Reduction Internal Fixation, IL: Interleukin, IQR: Interquartile range.

NRS Before and After Surgery	Laparoscopy	Laparotomy	ORIF	Removal Tumor	Stabilization and Decompression
NRS before surgery median (IQR)	1 (0-3)	1.5 (0-2)	2 (1-3)	1 (0-3)	1 (1-3)
NRS after surgery median (IQR)	3 (1-6)	4 (2-6)	3 (1-6)	3 (1-7)	3 (2-6)
р	0.001	0.001	0.01	0.001	0.04

Differences between before and after surgery groups in each surgical procedure were analyzed with Wilcoxon test. Bold figures indicate statistical significance. ORIF: Open reduction internal fixation, IL: Interleukin, IQR: Interquartile range, NRS: Numeric rating scale

(3-5 mcg/kg) when induction state. Some patients received additional dose of fentanyl in condition of increased blood pressure and heart rate due to pain stimulation during surgery with total fentanyl limitation up to 400 mcg.



Figure 9: Linear correlation between IL-6 after surgery and NRS after surgery in laparotomy procedure

Our study showed that mostly all surgical procedures resulted in a significant increase in IL-6 after surgery compare to IL-6 before surgery. In the contrary, there was no significant difference between IL-4 before surgery and IL-4 after surgery. Our data showed that the elevation of IL4 after surgery was not as high as IL6. The phenomenon might happen because IL4 is not fully secreted just after the surgery. Instead, it takes 24 h to be secreted to the entire body and 14 days for the optimal elevation [7]. The secretion of IL-4 performs as an anti-inflammatory response to the location of surgery. The variations of its level during each surgery are caused by different aggregation of the macrophages and other pro-inflammatory mediators residing in the surgical spot. The severity of tissue trauma from the surgery is in line with the IL-4 secretion [8].

Analysis by comparing the difference between the average of IL-6 before and after surgery (Δ IL6) confirmed that the laparotomy procedure had a higher degree of change in Δ IL-6 than other procedures. Several authors compared laparotomy with laparoscopy procedures in the digestive field. The comparison showed higher Δ IL-6 in laparotomy surgery due to more severe trauma to the tissue. Higher postoperative IL-6 values found in the laparotomy group correspond to greater surgical stress. Laparoscopy surgery incites less stress response and therefore is associated with a lesser tissue injury than laparotomy surgery. The evaluation between laparoscopic and laparotomy colorectal resection patients found higher IL-6 elevation in the laparotomy group due to more severe trauma to the tissue. [9] However, Dunker et al. did not find significantly different IL-6 or CRP concentrations between the laparoscopic and laparotomy surgery groups in patients undergoing ileocolic or colonic resection for regional enteritis or colectomy for ulcerative colitis or familial adenomatous polyposis.[10] Factors that may have affected the disparity in IL-6 measurements include heterogeneity of the patient populations, ie malignant versus benign diseases (such as regional enteritis), the complexity of the procedure performed, and the occurrence of perioperative complications [11].]



Figure 10: Linear correlation between length of operation and ΔIL-6

Table 5: The comparison of interleukins after surgery, NRS score, total fentanyl used, and length of surgery with surgical procedures

Interleviling NDO		1		Dama and Turner	Otabilization and December 2	Torrest and a statistic statement	
Fentanyl Dosage	Laparoscopy	Laparotomy	URIF	Removal Tumor	Stabilization and Decompression	rympanomasioideciomy	p value
and Lenght Of							
Surgery							
IL-4 after surgery,	3.74 (3–7.5)	3.59 (3–34.7)	3.87 (3.2–5.3)	3.72 (3.1–24.1)	3.53 (3.1–4.5)	3.5 (3.3–3.7)	0.95
median (IQR)							
IL-6 after surgery,	160 (65.1–515.2)	397.8 (90.4–2246.4)	197.8 (102–1862)	254.9 (82.8–1051)	163.7 (90–546)	429.9 (142.2–717.8)	0.03
median (IQR)							
NRS after surgery,	3 (1–6)	4 (2–6)	3 (1–6)	3 (1–7)	3 (2–6)	2.5 (1–4)	0.175
median (IQR)							
∆IL-4, median	0.09 ([-0.8]-3.7)	0.00 ([-3.2]-1.2)	0.14 ([-0.8]-0.7)	0.09 ([-1.8]-8.4)	0.00 ([-0.7]-0.9)	0.05 ([-0.1]-0.2)	0.88
(IQR)							
∆IL-6, median	42.4 ([-417]-399.4)	103.6 ([-26.6]-2010.4)	41.7 ([-3.2]-843.1)	43.5 ([-123.6]-448)	-3.5 ([-25.9]-54.7)	89.6 (61.1–118.1)	0.03
(IQR)							
∆NRS, median	1 (0-4)	2 (0–5)	1 (0–3)	2 (0–4)	2 (1–4)	1.5 (0–3)	0.03
(IQR)							
Total fentany	200 (100-500)	250 (250-250)	200 (100-400)	205 (100-400)	200 (100–300)	300 (300–300)	0.24
used (mg)							
Length of	2 (1–5)	2 (1.5–5)	2 (1–5)	3 (1–5)	3 (2–4)	4.5 (3-6)	0.13
surgery (h)							

*Differences between Interleukin, NRS, Total fentanyl used, and length of surgery in every surgical procedure were analyzed with Kruskal–Wallis test. Bold figures indicate statistical significance. ORIF: Open reduction internal fixation, IL: Interleukin, IQR: Interquartile range.

Open Access Maced J Med Sci. 2023 Jan 01: 11(A):1-7.

Table 6: The correlation of IL-4 and IL-6 after surgery with NRS score after surgery in each surgical procedure

Interleukins	All patients	NRS after surgery	NRS after surgery				
		Laparoscopy	Laparotomy	ORIF	Removal tumor	Stabilization and decompression	
IL-4 after surgery							
r	0.03	0.01	0.38	-0.11	-0.35	0.05	
р	0.73	0.97	0.06	0.73	0.87	0.93	
IL-6 after surgery							
r	0.25	-0.01	0.47	0.25	0.22	-0.10	
р	0.01	0.93	0.01	0.45	0.31	0.87	
*Correlation between Interleukin after surgery and NRS after surgery in each surgical procedure were analyzed with Spearman test. Bold figures indicate statistical significance. A: Delta, ORIF: Open reduction internal							

fixation, IL: Interleukin, NRS: Numeric rating scale.

We found that IL-6 after surgery and ∆IL-6 showed a significant correlation with the NRS after surgery and ΔNRS . The power of those coefficient correlations were strong enough with a positive trend, which means the elevation of IL-6 after surgery and Δ IL-6 influences the elevation of NRS after surgery and ΔNRS , respectively We also found that ΔNRS had a significant correlation with surgical procedures. Laparotomy had the highest Δ IL-6 level and highest ΔNRS value than other procedures. This result implies that high Δ IL6 may contribute to high Δ NRS in the laparotomy procedure. Sarah et al. found on chemotherapy-treated prostate cancer patients with (NRS 3) exhibited significant elevation of several pro-inflammatory cytokines, particularly IL-6. These findings suggest that the cytokines (IL-6, IL-8, Eotaxin, VEGF, and IP-10) that exhibited significant increases, particularly IL-6, are involved in the pathophysiology of chemotherapy-induced pain [12]. IL-6 is a powerful pro-inflammatory cytokine produced in response to peripheral nerve injury that mostly happens in a surgical procedure. It continues with the recruitment of other cytokines, promoting infiltration of T cells and then maintaining pain sensation [13].

Table 7: The correlation of ΔIL -4 and ΔIL -6 with ΔNRS score after surgery in each surgical procedure

Δ	All	ΔNRS				
Inerleukins	patients	Laparoscopy	Laparotomy	ORIF	Removal tumor	Stabilization and
						decompression
ΔIL-4						
r	-0.12	-0.16	0.15	0.42	-0.14	-0.66
р	0.23	0.43	0.46	0.19	0.53	0.21
ΔIL-6						
r	0.32	0.14	0.27	0.30	0.41	0.97
р	0.002	0.48	0.18	0.35	0.053	0.01
*Correlation between Alpterleukin and ANRS in each surgical procedure were analyzed with Spearman						

test. Bold figures indicate statistical significance. Δ: Delta, ORIF: Open reduction internal fixation, L1: Interlewin, NRS: Numeric rating scale.

We also found that the length of surgery significantly correlates with Δ IL-6. Duration of surgical procedure may affect IL-6 release. Our data form comparing Δ IL-6 and length of surgical procedures showed a strong enough coefficient correlation and

Table 8: Correlation between Total Fentanyl Used and Length of Operation with ΔIL -4 and ΔIL -6

Total Fentanyl and Operation Length Factors	ΔIL-4 (pg/mL)	ΔIL-6 (pg/mL)
Total fentanyl used		
r	0.093	-0.069
p	0.381	0.519
Length of operation		
r	-0.169	0.279
p	0.112	0.008

Correlation between total fentanyl used and length of operation with Δ IL-4 and Δ IL-6 were analyzed with Spearman test. Bold figures indicate statistical significance. Δ : Delta, IL: Interleukin

positive trend. The study reported by Leung *et al.* reveals a similar elevation of IL-6 postoperative level during 48–72 h. The data suggest an elevation of IL-6 in every period of surgery [14]. Tzu-Chi Hsu also found there was an elevated trend of IL-6 concentration two hours after surgery and declined to baseline 48 hours after surgery [4]. Trauma caused by surgery will lead to an increased level of IL-6 during the 3 hours of surgery and will probably increase until 72 h [15].

Limitation

This study was conducted on samples that underwent different types of surgery. We also did not follow serial interleukin and NRS changes from the beginning and after surgery.

Conclusions

We conclude that every surgery could influence different responses to produce IL-6. The variation of IL-6 concentration may contribute to the Δ NRS discrepancy. Laparotomy procedures with high tissue stress may trigger the elevation of Δ IL-6 and stimulate high pain intensity.

References

 Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised international association for the study of pain definition of pain: Concepts, challenges, and compromises. Pain. 2020;161(9):1976-82. https://doi.org/10.1097/j. pain.000000000001939

PMid:32694387

- Venkatraman R, Pushparani A, Balaji R, Nandhini P. Comparison of low dose intravenous fentanyl and morphine infusion for postoperative analgesia in spine fusion surgeries-a randomized control trial. Braz J Anesthesiol. 2021;71(4):339-44. https://doi. org/10.1016/j.bjane.2020.12.013 PMid:34229859
- Metcalfe RD, Putoczki TL, Griffin MD. Structural understanding of interleukin 6 family cytokine signaling and targeted therapies: Focus on interleukin 11. Front Immunol. 2020;11:1424. https:// doi.org/10.3389/fimmu.2020.01424
 PMid:32765502

- Hsu TC, Lin CH, Sun FJ, Chen MJ. Postoperative serum levels of interleukin-6 are affected by age in patients with colorectal cancer. Int J Gerontol. 2017;11(2):75-9. https://doi.org/10.1016/j. ijge.2016.06.004
- Vanderwall AG, Milligan ED. Cytokines in pain: Harnessing endogenous Anti-inflammatory signaling for improved pain management. Front Immunol. 2019;10:3009. https://doi. org/10.3389/fimmu.2019.03009
 PMid:31921220
- Celik MÖ, Labuz D, Keye J, Glauben R, Machelska H. IL-4 induces M2 macrophages to produce sustained analgesia via opioids. JCI insight. 2020;5(4):e133093. https://doi.org/10.1172/ jci.insight.133093

PMid:32102987

- Dobson GP, Morris JL, Biros E, Davenport LM, Letson HL. Major surgery leads to a proinflammatory phenotype: Differential gene expression following a laparotomy. Ann Med Surg (Lond). 2021;71:102970. https://doi.org/10.1016/j.amsu.2021.102970 PMid:34745602
- Modolin ML, Cintra W Jr., Rocha RI, Camargo CP, de Rossa Giuliani N, de Souza HP, *et al.* Analysis of inflammatory and metabolic biomarkers in patients submitted to abdominoplasty after bariatric surgery. Acta Cir Bras. 2019;34(5):e201900506. https://doi.org/10.1590/s0102-865020190050000006 PMid:31166465
- Rettig TC, Verwijmeren L, Dijkstra IM, Boerma D, van de Garde EM, Noordzij PG. Postoperative interleukin-6 level and early detection of complications after elective major abdominal surgery. Ann Surg. 2016;263(6):1207-12. https://doi. org/10.1097/SLA.00000000001342 PMid:26135695
- Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. Interleukin-6 in surgery, trauma, and criticial care part II: Clinical

implications. J Intensive Care Med. 2017;26(2):73-87. https:// doi.org/10.1177/0885066610384188 PMid:21464062

- Kwok CH, Learoyd AE, Canet-Pons J, Trang T, Fitzgerald M. Spinal interleukin-6 contributes to central sensitisation and persistent pain hypersensitivity in a model of juvenile idiopathic arthritis. Brain Behav Immun. 2020;90:145-54. https://doi. org/10.1016/j.bbi.2020.08.004 PMid:32791212
- Al-Mazidi S, Farhat K, Nedjadi T, Chaudhary A, Zin Al-Abdin O, Rabah D, et al. Association of interleukin-6 and other cytokines with self-reported pain in prostate cancer patients receiving chemotherapy. Pain Med. 2018;19(5):1058-66. https://doi. org/10.1093/pm/pnx145

PMid:29016954

- Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. 2010;229(1-2):26-50. https://doi.org/10.1016/j.jneuroim.2010.08.013 PMid:20870295
- 14. Yu XZ, Lu S, Gou W, Wang W, Zou SH, Han YX, *et al.* Assessment of the characteristics and quality of life of patients with uremic peripheral neuropathy. Clin Nephrol. 2017;87(3):134-9. https:// doi.org/10.5414/CN108913

PMid:28102815

 Roumen RM, Hendriks T, Van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauerwein RW, Van der Meer JW, *et al.* Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg. 1993;218(6):769-76. https://doi. org/10.1097/00000658-199312000-00011 PMid:8257227